Skip to main content
CBLLCeriBell, Inc.Sell5.6·$27.39
SellModerate Confidence

Thesis pillars

  • Strong Revenue Growth→Stable
  • Cash Burn Weak Quality→Stable
  • Price Above Analyst Target↓Deteriorating
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Oct 24, 2026, based on the 10-K filed Feb 24, 2026

Full reasoning →

Open full analysis

CeriBell, Inc. (CBLL) Stock Analysis

Range Bound setup

SellVALUE-TRAP 2/5GrowthQualityModerate Confidence

Healthcare · Medical Devices

Sell if holding. Engine safety override at $27.39: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality.

CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an AI-powered algorithm for detecting seizures and, since a December 2025 clearance, delirium in critically ill patients. The company generated 88% gross margins in fiscal... Read more

$27.39+0.3% A.UpsideScore 5.6/10#23 of 62 Medical Devices
QualityF-score6 / 9FCF yield-3.10%
Stop $25.47Analyst target $27.47(−13% haircut)A.R:R 0.0:1
Analyst consensus$31.57+15.3%7 analysts with price targets
$27.47Analyst target
$27.39price
$31.57mean
$33

Sell if holding. Engine safety override at $27.39: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 5.6/10, moderate confidence.

Passes 6/8 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 93d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Nov 5, 2026

Recent Developments — CeriBell, Inc.

Latest item Nov 5, 2026 · Generated 2026-11-22T11:47:06Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Feb 23, 202793d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Product: Ceribell System
Concentration risk — Geographic: United States sales (100.0%)
Target reached (0.3% upside)

Key Metrics

P/E (TTM)—
P/E (Fwd)-16.0
Mkt Cap$1.1B
EV/EBITDA-12.9
Profit Mgn-68.0%
ROE-52.5%
Rev Growth29.9%
Beta0.86
DividendNone
Analysts with ratings14

Quality Signals

Piotroski F6/9MoatNarrow

Options Flow

P/C0.70neutral
IV87%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductCeribell System
    10-K Item 1A: 'We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.'
  • HIGHGeographicUnited States sales100%
    10-K Item 1A: 'To date, all of our sales have been to customers in the United States.'
  • HIGHSuppliertwo primary contract manufacturers in China
    10-K Item 1A: 'We rely on two primary contract manufacturers in China and maintain contractors in China who perform monitoring and quality inspection services.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker·1 ceiling hit

Unprofitable operations — net margin -68.0%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Rule Of 40
3.0
Current Ratio
5.0
Piotroski F
6.7
Moat
7.2
Gross Margin
10.0
Cash-burning: FCF -30% of revenueRule of 40: -0 (fail)
GatesA.R:R 0.0 < 1.5@spotINSIDER 0.33%=HEAVYMomentum 5.8>=5.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 93d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
52 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $21.85Resistance $28.89

Price Targets

$25
$27
A.Upside+0.3%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Target reached (0.3% upside)
! Quality below floor (3.2 < 4.0)
! Value-trap signals (2/5): Margin compression (op margin 1.6%), Material insider selling (20 sells, 0.19% of cap)

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-02-23 (93d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CBLL stock a buy right now?

Sell if holding. Engine safety override at $27.39: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $25.47. Score 5.6/10, moderate confidence.

What is the CBLL stock price target?

Analyst target: $27.47 (+0.3% upside). Prior stop was $25.47. Stop-loss: $25.47.

What are the risks of investing in CBLL?

Concentration risk — Product: Ceribell System; Concentration risk — Geographic: United States sales (100.0%); Target reached (0.3% upside).

Is CBLL overvalued or undervalued?

CeriBell, Inc. trades at a P/E of N/A (forward -16.0). TrendMatrix value score: 4.4/10. Verdict: Sell.

What do analysts say about CBLL?

14 analysts rate CBLL, with a consensus score of 4.4/5. 7 analysts publish price targets averaging $32.

What does CeriBell, Inc. do?CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an...

CeriBell has developed the Ceribell System, an FDA-cleared point-of-care EEG platform paired with Clarity, an AI-powered algorithm for detecting seizures and, since a December 2025 clearance, delirium in critically ill patients. The company generated 88% gross margins in fiscal 2025 from a recurring revenue model combining disposable Wearable sales and Clarity/portal subscription fees, has deployed to more than 600 U.S. hospitals, and to date has sold exclusively to customers in the United States. CeriBell relies on two primary contract manufacturers in China for assembly of its disposable Wea

Related stocks: DCTH (Delcath Systems, Inc.) · PODD (Insulet Corporation) · MASS (908 Devices Inc.) · BVS (Bioventus Inc.) · SENS (Senseonics Holdings, Inc.)
Home › Stocks › CBLL

Latest news

Latest News

Fiscal.ai17d agoAnalyst
Benzinga18d agoAnalyst
Fiscal.ai18d agoAnalyst
Benzinga19d agoEarnings
Fiscal.ai19d ago
Benzinga19d agoEarnings
Benzinga19d agoEarnings
Fiscal.ai20d agoProduct
Benzinga20d agoProduct
Fiscal.ai25d ago
Fiscal.ai33d agoEarnings
Benzinga51d agoAnalyst
Benzinga53d agoFda Decision
Benzinga96d agoAnalyst
Benzinga96d agoAnalyst
Benzinga103d ago
Benzinga104d agoEarnings
Benzinga104d agoEarnings
Benzinga104d agoFda Decision
Benzinga111d agoFda Decision